Ovarian Cancer Clinical Trials

153 studies are recruiting for ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   11 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

2. A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

   This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   4 in total

   Run by

   Persevere Therapeutics Inc.

   See if you can join NCT03854110 on ClinicalTrials.gov

3. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

   Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To o…

   Stage

   Not phased

   Ages

   3 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01441089 on ClinicalTrials.gov

4. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest /ID# 283487, Grand Rapids, Michigan

   Locations

   3 in total

   Run by

   AbbVie

   See if you can join NCT07807956 on ClinicalTrials.gov

5. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

   This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   11 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05287451 on ClinicalTrials.gov

6. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Denver, Colorado

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

7. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   198 in total

   Run by

   Incyte Corporation

   See if you can join NCT07214779 on ClinicalTrials.gov

8. EHR Intervention to Increase HBOC Genetic Testing

   The purpose of this research study is to test how well a new approach - using tools built into the electronic health record (EHR)- can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who have a family history that puts them at higher risk. The study will also …

   Stage

   Not phased

   Ages

   21 to 75

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT07876349 on ClinicalTrials.gov

9. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

   This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Santa Monica, California

   Locations

   67 in total

   Run by

   AstraZeneca

   See if you can join NCT05123482 on ClinicalTrials.gov

10. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    26 in total

    Run by

    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

11. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 as a monotherapy and in combination with bevacizumab (or a …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Denver, Aurora, Colorado

    Locations

    11 in total

    Run by

    Accent Therapeutics

    See if you can join NCT06799065 on ClinicalTrials.gov

12. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Alabama at Birmingham ( Site 0006), Birmingham, Alabama

    Locations

    198 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

13. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

    Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla, California

    Locations

    86 in total

    Run by

    AbbVie

    See if you can join NCT07059845 on ClinicalTrials.gov

14. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

    Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. Thi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 281381, Duarte, California

    Locations

    27 in total

    Run by

    AbbVie

    See if you can join NCT07278336 on ClinicalTrials.gov

15. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Alabama - Birmingham ( Site 0058), Birmingham, Alabama

    Locations

    167 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07318558 on ClinicalTrials.gov

16. A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

    This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT07389239 on ClinicalTrials.gov

17. Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

    The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are subs…

    Stage

    Not phased

    Ages

    50 to 74

    Site

    Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine, Miami, Florida

    Locations

    12 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT00539162 on ClinicalTrials.gov

18. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

    Stage

    Phase 1

    Ages

    15 and older

    Site

    City of Hope, Duarte, California

    Locations

    27 in total

    Run by

    Xencor, Inc.

    See if you can join NCT06276491 on ClinicalTrials.gov

19. Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

    The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05123807 on ClinicalTrials.gov

20. Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

    To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06036810 on ClinicalTrials.gov

21. Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

    This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinu…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    9 in total

    Run by

    Genmab

    See if you can join NCT07564141 on ClinicalTrials.gov

22. Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mt. Sinai Comprehensive Cancer Center, Miami, Florida

    Locations

    34 in total

    Run by

    Genmab

    See if you can join NCT07225270 on ClinicalTrials.gov

23. Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

    Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Ge…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kings County Hopsital Center, Brooklyn, New York

    Locations

    4 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04751435 on ClinicalTrials.gov

24. Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    4 in total

    Run by

    Imunon

    See if you can join NCT05739981 on ClinicalTrials.gov

25. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage

    Phase 1

    Ages

    18 to 130

    Site

    Research Site, Duarte, California

    Locations

    60 in total

    Run by

    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov